Evommune's lead drug fails in chronic hives, stock sinks

June 29, 2026 10:45 AM EDT R&D Evom­mune's lead drug fails in chron­ic hives, stock sinks Max Gelman Senior Editor Evom­mune’s shares $EVMN fell more than 30% on Mon­day morn­ing af­ter the biotech re­port­ed its first ma­jor tri­al read­out since go­ing pub­lic last year. In … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER